XBiotech (XBIT) Reports Publication of Phase 2 Data from Hidradenitis Suppurativa Phase 2 Study
Tweet Send to a Friend
XBiotech Inc. (NASDAQ: XBIT) announced today the publication of data from its randomized phase 2 study evaluating XBiotech’s True Human™ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
